Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PSMA-targeted Docetaxel Nanoparticles BIND-014

Known as: BIND-014 
A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane… Expand
National Institutes of Health

Related topics

Related topics

2 relations
Microtubule ProcessNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
PLGA-Based Nanoparticles in Cancer Treatment
Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug delivery, hyperthermia, and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2018
2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial
Importance Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)–targeted nanoparticles is… Expand
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2016
2016
A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
233 Background: BIND-014 is a novel PSMA-targeted Accurin (polymeric nanoparticle) that contains docetaxel (D). BIND-014 is… Expand
Is this relevant?
Review
2014
Review
2014
Targeted therapy using nanotechnology: focus on cancer
Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2013
2013
Abstract LB-203: A phase I study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, in patients with refractory solid tumors.
Background: BIND-014 is a novel, targeted, polymeric nanoparticle (NP) containing docetaxel (DTXL). BIND-014 is targeted to… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
First plant-made biologic approved
  • J. Fox
  • Nature Biotechnology
  • 2012
    • Corpus ID: 30936119
The US Food and Drug Administration in May approved Elelyso (taliglucerase alfa), an enzyme produced in genetically engineered… Expand
Is this relevant?
Review
2012
Review
2012
Nanoparticle therapeutics for prostate cancer treatment.
The application of nanotechnology in medicine is offering many exciting possibilities in healthcare. Engineered nanoparticles… Expand
Is this relevant?
Review
2012
Review
2012
Nanoparticle therapeutics for prostate cancer treatment.
The application of nanotechnology in medicine is offering many exciting possibilities in healthcare. Engineered nanoparticles… Expand
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Proof of concept for next-generation nanoparticle drugs in humans
  • C. Sheridan
  • Nature Biotechnology
  • 2012
    • Corpus ID: 205268802
471 “The thing it had in common was the long circulation time.” The current generation of nanoparticles varies widely in size… Expand
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE